NASDAQ:IMMP
Immutep Ltd Stock News
$3.23
+0.130 (+4.19%)
At Close: May 21, 2024
Immutep shares soar 190% on positive results in trial of breast cancer treatment
11:31am, Thursday, 10'th Dec 2020
Shares of Immumetp Ltd., an Australian biotech with a Nasdaq listing, soared 190% Thursday, after the company reported positive results from a trial of a treatment for metastatic breast cancer.
Immutep's Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study
05:53pm, Wednesday, 09'th Dec 2020
Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is
Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pl
Immutep Announces Expansion of TACTI-002 Collaboration Trial
06:19pm, Wednesday, 18'th Nov 2020
SYDNEY, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces it is advancing clinical development for its lead product candidate eftilagimod alpha (“efti�
Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development
05:59pm, Wednesday, 18'th Nov 2020
Sydney, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (“Immutep“ or the “Company“), which is liste
Immutep's Phase II TACTI-002 Study Reports Encouraging Data at SITC
04:10pm, Monday, 09'th Nov 2020
Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release �
Immutep's TACTI-002 Data to Be Presented at Society for Immunotherapy of Cancer 2020 Annual Meeting
05:24pm, Monday, 02'nd Nov 2020
SYDNEY, Australia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments fo
Immutep to Collaborate with LabCorp to Develop Oncology Services and Products
08:45am, Thursday, 29'th Oct 2020
SYDNEY, Australia, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is p
Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study
12:00pm, Tuesday, 18'th Aug 2020
* 23 patients with second line Non-Small Cell Lung Cancer (NSCLC) participating in Stage 1, Part B * Total of 87 patients out of up to 109 patients (80%) are enrolled and participating in the trial
Immutep Issues Newsletter Update to Shareholders
12:00pm, Monday, 17'th Aug 2020
LAG-3 Therapeutic Landscape Overview Formatted version of this update available on the Company’s website www.immutep.comSYDNEY, Australia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM
Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
12:00pm, Tuesday, 11'th Aug 2020
SYDNEY, Australia, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for
A Look At Immutep's (ASX:IMM) Share Price Returns
09:36pm, Tuesday, 21'st Jul 2020
Immutep Limited (ASX:IMM) has rebounded strongly over the last week, with the share price soaring 45%. But don't envy...
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
11:30am, Wednesday, 15'th Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) * Altimmune Inc (NASDAQ: ALT) (priced its $115 millio
Immutep Announces United States Patent Grant for IMP701 Antibody
11:00pm, Tuesday, 14'th Jul 2020
SYDNEY, Australia, July 15, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 10,711,060 entitled “Antibody.
Immutep Completes Recruitment for Part A of Phase II TACTI-002 Study
12:00pm, Monday, 29'th Jun 2020
Completes recruitment of patients with first line Non-Small Cell Lung Cancer (NSCLC)81 patients out of up to 109 now participating across the trial, with recruitment continuing.
